Recent PTAB Decision Highlights Importance of Secondary Considerations in Obviousness Challenges

Jun 2, 2017

Reading Time : 1 min

By: Rubén H. Muñoz, Lance Han, law clerk (not admitted to practice)

The patent at issue in Varian Medical Systems is U.S. Pat. No. 7,471,765 B2 (the “’765 patent”), which generally relates to using a cone-beam CT scanner with a flat-panel imager in conjunction with a radiation therapy system as an image-guided radiotherapy system for increased precision and effectiveness of radiation treatments. The petitioners argued, and the PTAB agreed, that all claim limitations were taught by the combination of prior art references. However, the PTAB also assessed “secondary considerations” in its obviousness inquiry. In doing so, the PTAB found “(1) very strong evidence of industry praise; (2) very strong evidence of long-felt need; (3) moderately strong evidence of commercial success; and (4) moderately strong evidence of copying,” pointing to the nonobvious nature of the ’765 patent and its claims. First, for industry praise, the PTAB found evidence of textbook publications praising the invention, journal publications (“more than 1,000 . . . scientific articles”) citing the invention, and an R&D award from a magazine in 2006. Second, for long-felt need, the PTAB analyzed evidence such as the patent owner’s declaration and deposition testimony, and a journal publication that supported the patent owner’s assertion that the problem the patent purported to solve “need[ed] to be solved, and that it was long-felt at least since ‘the early 1990s.’”  Third, for commercial success, the PTAB found evidence that the majority of sales both worldwide and in North America were made with the claimed invention. Lastly, for copying, the PTAB found evidence that a third party created a product that met all claim limitations.

As a result, despite finding that the prior art, and the combinations of those prior art references, were “well known to one of ordinary skill in the art,” the PTAB ruled that the patent owner’s evidence of secondary considerations, which strongly pointed to nonobviousness, outweighed those findings and thus rejected the petitioner’s obviousness challenge.

Varian Medical Systems, Inc. v. William Beaumont Hospital, IPR2016-00162, Paper 69 (May 4, 2017).

Share This Insight

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.